Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 11/20 | 0.66 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | DRD5 | P21918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17457970 | 1.00 | PIK3CD (0.66) | PIK3CDHTR1AHRH3DRD3KCNH2 | |
| SCHEMBL17458351 | 0.93 | PIK3CD (0.66) | PIK3CDHRH3KCNH2 | |
| SCHEMBL17458105 | 0.93 | PIK3CD (0.66) | PIK3CDHRH3KCNH2 | |
| SCHEMBL17458329 | 0.93 | PIK3CD (0.66) | PIK3CDHRH3KCNH2 | |
| SCHEMBL17458327 | 0.93 | PIK3CD (0.66) | PIK3CDHRH3KCNH2 | |
| SCHEMBL17458349 | 0.93 | PIK3CD (0.66) | PIK3CDHRH3KCNH2 | |
| SCHEMBL17458104 | 0.93 | PIK3CD (0.66) | PIK3CDHRH3KCNH2 | |
| SCHEMBL17458389 | 0.92 | PIK3CD (0.66) | PIK3CDHRH3KCNH2DRD1DRD5 | |
| SCHEMBL17458387 | 0.92 | PIK3CD (0.66) | PIK3CDHRH3KCNH2DRD1DRD5 | |
| SCHEMBL17458372 | 0.87 | PIK3CD (0.66) | PIK3CDHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160960-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20180065953-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9765060-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160024054-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065953-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, PIK3R5, PIK3R4 | PIK3CD 8/4885HTR1A 2671/4885HRH3 1591/4885 |
| US-20160024054-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3R4, PIK3CA | PIK3CD 9/4885HTR1A 3389/4885HRH3 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.